Medical devices, healthcare technology and the business of care
PMA approval · P240015

Womed Leaf Resorbable Adhesion Barrier

Womed Sas · Decision date Sep 9, 2025

FDA DECISIONP240015

What did the FDA approve?

FDA records P240015 as an original PMA application. The recorded decision is approval, dated Sep 9, 2025.

FDA approval order statement

Approval for the Womed Leaf Resorbable Adhesion Barrier is intended to reduce the reoccurrence and severity of post-surgical adhesion formation inside the uterus. It is indicated for adult women undergoing hysteroscopic surgery for symptomatic moderate to severe intrauterine adhesions.
Regulatory pathway
Original PMA
Clinical specialty
Obstetrics/Gynecology
Decision date
Sep 9, 2025

FDA source record

Regulatory record facts

Identifier
P240015
Regulatory pathway
Premarket approval application
Applicant
Womed Sas
Product code
MCN
Decision code
APPR
Decision date
Sep 9, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Barrier, absorbable, adhesion.

Applicant
Womed Sas
Product code
MCN
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P240015 received

    Application receipt date recorded by FDA.

  2. P240015 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P240015. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240015

Product / regulatory recordCompanyPathwayDecision dateSource
Womed LeafP240015/S003
Womed SasPMA supplementOct 25, 2026FDA

Explore the linked device profile

Other records with product code MCN

Product / regulatory recordCompanyPathwayDecision dateSource
ETHICON, Inc.PMA supplementNov 5, 2026FDA
Rejoni, Inc.PMA supplementOct 28, 2026FDA
Rejoni, Inc.PMA approvalSep 28, 2026FDA
ETHICON, Inc.PMA approvalSep 15, 1989FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Womed Sas

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Batiment Balard Cit, 1919 Rte. De Mende, Montpellier, 34090

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records